Low-grade serous ovarian cancer is a rare, slow-growing cancer that is generally resistant to cytotoxic chemotherapy. In the upfront setting, treatment recommendations mimic those of high-grade serous ovarian cancer.
A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.
A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.
Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.